Pharvaris presents Phase 3 deucrictibant data at ACAAI annual scientific meeting
PHVS•Pharvaris will present Phase 3 CHAPTER-3 data on extended-release deucrictibant for hereditary angioedema attack prevention at the ACAAI meeting, alongside five posters.
1. Meeting presentations
Pharvaris will present at the ACAAI Annual Scientific Meeting in Phoenix, Arizona, November 12-16, 2026. A late-breaking oral presentation on November 14 will feature Phase 3 CHAPTER-3 data on extended-release deucrictibant for hereditary angioedema attack prevention; five posters scheduled for November 13-15 will cover additional clinical and real-world data.
